Eton Pharmaceuticals, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Eton Pharmaceuticals, Inc. (ETON) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$739.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.01M, a 55.89% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.75M.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.52M, a 28.38% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $122.00K, a 23.27% decline year-over-year.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.97M, a 41.15% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $3.35M.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$94.00K.
- Eton Pharmaceuticals, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.84M, a 279.34% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 5 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 8 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$739.00K 10-Q · filed 2026-08-13 | $1.78M derived: sum of 3 quarters · filed 2026-08-13 | $1.90M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$1.75M 10-Q · filed 2026-05-14 | $767.00K derived: sum of 2 quarters · filed 2026-05-14 | $889.00K derived: sum of 3 quarters · filed 2026-05-14 | $3.19M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.64M derived: sum of 2 quarters · filed 2026-03-19 | $4.94M derived: sum of 3 quarters · filed 2026-08-13 | $1.97M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.42M derived: sum of 2 quarters · filed 2026-08-13 | -$550.00K 10-Q · filed 2025-11-06 | $2.97M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$672.00K 10-Q · filed 2026-08-13 | $2.85M derived: sum of 3 quarters · filed 2026-08-13 | $3.01M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$2.97M 10-Q · filed 2026-05-14 | $547.00K derived: sum of 2 quarters · filed 2026-05-14 | $706.00K derived: sum of 3 quarters · filed 2026-05-14 | $455.00K derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.68M derived: sum of 2 quarters · filed 2026-03-19 | $3.43M derived: sum of 3 quarters · filed 2026-03-19 | $3.35M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$92.00K derived: sum of 2 quarters · filed 2025-11-06 | -$171.00K 10-Q · filed 2025-11-06 | $484.00K derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-06-30 | -$251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$330.00K 10-Q · filed 2025-08-07 | $325.00K derived: sum of 3 quarters · filed 2026-03-19 | -$1.00K derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2024-03-31 | -$79.00K 10-Q · filed 2025-05-13 | $576.00K derived: sum of 2 quarters · filed 2026-03-19 | $250.00K derived: sum of 3 quarters · filed 2026-03-19 | $18.00K derived: sum of 4 quarters · filed 2026-03-19 | |||
| 2023-12-31 | $655.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $329.00K derived: sum of 2 quarters · filed 2026-03-19 | $97.00K derived: sum of 3 quarters · filed 2026-03-19 | -$94.00K 10-K · filed 2026-03-19 | -$161.00K 10-K · filed 2024-03-14 | ||
| 2023-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$558.00K derived: sum of 2 quarters · filed 2024-11-12 | -$749.00K 10-Q · filed 2024-11-12 | -$460.00K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | -$232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$423.00K 10-Q · filed 2024-08-08 | -$134.00K derived: sum of 3 quarters · filed 2025-03-18 | -$436.00K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-03-31 | -$191.00K 10-Q · filed 2024-05-09 | $98.00K derived: sum of 2 quarters · filed 2025-03-18 | -$204.00K derived: sum of 3 quarters · filed 2025-03-18 | -$1.07M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$13.00K derived: sum of 2 quarters · filed 2025-03-18 | -$879.00K derived: sum of 3 quarters · filed 2025-03-18 | -$1.84M 10-K · filed 2025-03-18 | -$1.90M 10-K · filed 2023-03-16 | ||
| 2022-09-30 | -$302.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.17M derived: sum of 2 quarters · filed 2023-11-09 | -$2.13M 10-Q · filed 2023-11-09 | -$1.39M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | -$866.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.83M 10-Q · filed 2023-08-10 | -$1.08M derived: sum of 3 quarters · filed 2024-03-14 | -$382.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$961.00K 10-Q · filed 2023-05-11 | -$218.00K derived: sum of 2 quarters · filed 2024-03-14 | $484.00K derived: sum of 3 quarters · filed 2024-03-14 | -$781.00K derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.45M derived: sum of 2 quarters · filed 2024-03-14 | $180.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.03M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | $702.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$563.00K derived: sum of 2 quarters · filed 2022-11-10 | $283.00K 10-Q · filed 2022-11-10 | $1.61M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$419.00K 10-Q · filed 2022-08-11 | $906.00K derived: sum of 3 quarters · filed 2023-03-16 | $852.00K derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2021-03-31 | $846.00K 10-Q · filed 2022-05-12 | $2.17M derived: sum of 2 quarters · filed 2023-03-16 | $2.12M derived: sum of 3 quarters · filed 2023-03-16 | $1.89M derived: sum of 4 quarters · filed 2023-03-16 | |||
| 2020-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.27M derived: sum of 2 quarters · filed 2023-03-16 | $1.04M derived: sum of 3 quarters · filed 2023-03-16 | $20.00K 10-K · filed 2023-03-16 | |||
| 2020-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | -$285.00K derived: sum of 2 quarters · filed 2021-11-16 | -$1.30M 10-Q · filed 2021-11-16 | $482.00K derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-06-30 | -$231.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$1.25M 10-Q · filed 2021-08-16 | $536.00K derived: sum of 3 quarters · filed 2022-03-16 | -$942.00K derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2020-03-31 | -$1.02M 10-Q · filed 2021-05-13 | $767.00K derived: sum of 2 quarters · filed 2022-03-16 | -$711.00K derived: sum of 3 quarters · filed 2022-03-16 | -$846.00K derived: sum of 4 quarters · filed 2022-03-16 | |||
| 2019-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $309.00K derived: sum of 2 quarters · filed 2022-03-16 | $174.00K derived: sum of 3 quarters · filed 2022-03-16 | $1.36M 10-K · filed 2022-03-16 | |||
| 2019-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.61M derived: sum of 2 quarters · filed 2020-11-12 | -$426.00K 10-Q · filed 2020-11-12 | -$256.00K derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-06-30 | -$135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.05M 10-Q · filed 2020-08-12 | $1.22M derived: sum of 3 quarters · filed 2021-03-16 | $1.41M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2019-03-31 | $1.19M 10-Q · filed 2020-05-14 | $1.36M derived: sum of 2 quarters · filed 2021-03-16 | $1.55M derived: sum of 3 quarters · filed 2021-03-16 | $1.72M derived: sum of 4 quarters · filed 2021-03-16 | |||
| 2018-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $359.00K derived: sum of 2 quarters · filed 2021-03-16 | $534.00K derived: sum of 3 quarters · filed 2021-03-16 | $663.00K 10-K · filed 2021-03-16 | |||
| 2018-09-30 | $189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $364.00K derived: sum of 2 quarters · filed 2019-11-14 | $493.00K 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $304.00K 10-Q · filed 2019-08-06 | |||||
| 2018-03-31 | $129.00K 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | $170.00K 10-K · filed 2020-03-05 | ||||||
| 2017-09-30 | $153.00K 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |